Prevention of hepatitis C virus infection using a broad cross‐neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Liver transplantation

• Publication date

  2015-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/lt.24344PMID 26389583PMCID PMC4769112
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hepatitis C and liver transplantation.

  2018cited by this paper
• TREATING HEPATITIS C INFECTION

  2017cited by this paper
• Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action

  2015influential reference
• Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.

  2015cited by this paper
• Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.

  2015cited by this paper
• Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a

  2014cited by this paper
• Comparison of in vitro antiviral activity of tea polyphenols against influenza A and B viruses and structure-activity relationship analysis.

  2014cited by this paper
• Will There Be a Vaccine to Prevent HCV Infection?

  2014cited by this paper
• Recombinant Hepatitis C Virus Envelope Glycoprotein Vaccine Elicits Antibodies Targeting Multiple Epitopes on the Envelope Glycoproteins Associated with Broad Cross-Neutralization

  2014cited by this paper
• Treatment of hepatitis C: a systematic review.

  2014cited by this paper
• Antiviral treatment of hepatitis C

  2014cited by this paper
• Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.

  2014cited by this paper
• A Hepatitis C Virus (HCV) Vaccine Comprising Envelope Glycoproteins gpE1/gpE2 Derived from a Single Isolate Elicits Broad Cross-Genotype Neutralizing Antibodies in Humans

  2013cited by this paper
• A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation

  2013cited by this paper
• Human Monoclonal Antibody MBL‐HCV1 Delays HCV Viral Rebound Following Liver Transplantation: A Randomized Controlled Study

  2013cited by this paper
• (−)‐Epigallocatechin‐3‐gallate is a new inhibitor of hepatitis C virus entry

  2012cited by this paper
• Human Monoclonal Antibody HCV1 Effectively Prevents and Treats HCV Infection in Chimpanzees

  2012cited by this paper
• Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus

  2012cited by this paper
• The role of neutralizing antibodies in hepatitis C virus infection.

  2012cited by this paper
• In vivo evaluation of the cross‐genotype neutralizing activity of polyclonal antibodies against hepatitis C virus

  2011cited by this paper
• The green tea polyphenol, epigallocatechin‐3‐gallate, inhibits hepatitis C virus entry

  2011cited by this paper
• Neutralizing Antibody Response to Hepatitis C Virus

  2011cited by this paper
• Recent Advances in Hepatitis C Virus Cell Entry

  2010cited by this paper
• Hepatotoxicity of high oral dose (-)-epigallocatechin-3-gallate in mice.

  2010cited by this paper
• Lipoprotein profiles in SCID/uPA mice transplanted with human hepatocytes become human-like and correlate with HCV infection success.

  2010cited by this paper
• Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity

  2009cited by this paper
• Green tea (Camellia sinensis) for the prevention of cancer.

  2009cited by this paper
• Development and characterization of hepatitis C virus genotype 1‐7 cell culture systems: Role of CD81 and scavenger receptor class B type I and effect of antiviral drugs

  2009cited by this paper
• The natural history of recurrent hepatitis C and what influences this

  2008cited by this paper
• Clinical Benefits of Antiviral Therapy in Patients with Recurrent Hepatitis C Following Liver Transplantation

  2008cited by this paper
• Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge

  2008cited by this paper
• Liver and Intestine Transplantation in the United States, 1997–2006

  2008cited by this paper
• Hepatitis C vaccine: supply and demand.

  2008cited by this paper
• Hepatitis C therapy before and after liver transplantation

  2008cited by this paper
• Tea polyphenols for health promotion.

  2007cited by this paper
• Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus

  2007cited by this paper
• Methylation suppresses the proteasome‐inhibitory function of green tea polyphenols

  2007cited by this paper
• Treating hepatitis C infection in liver transplant recipients

  2006cited by this paper
• DOSE-DEPENDENT LEVELS OF EPIGALLOCATECHIN-3-GALLATE IN HUMAN COLON CANCER CELLS AND MOUSE PLASMA AND TISSUES

  2006cited by this paper
• Liver and Intestine Transplantation in the United States, 1995–2004

  2006cited by this paper
• Monoclonal antibody HCV‐AbXTL68 in patients undergoing liver transplantation for HCV: Results of a phase 2 randomized study

  2006cited by this paper
• Antiviral treatment of hepatitis C

  2006cited by this paper
• Anti‐HCV therapies in chimeric scid‐Alb/uPA mice parallel outcomes in human clinical application

  2006cited by this paper
• Hepatitis C and liver transplantation

  2005cited by this paper
• Peginterferon alfa‐2a for hepatitis C after liver transplantation: Two randomized, controlled trials

  2005cited by this paper
• A randomized, open‐label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients

  2005cited by this paper
• Complete Replication of Hepatitis C Virus in Cell Culture

  2005cited by this paper
• Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: structure-activity relationship and molecular-modeling studies.

  2005cited by this paper
• Peginterferon Alfa-2 a for Hepatitis C After Liver Transplantation : Two Randomized , Controlled Trials

  2005cited by this paper
• Monoclonal Antibody AP33 Defines a Broadly Neutralizing Epitope on the Hepatitis C Virus E2 Envelope Glycoprotein

  2005cited by this paper
• Plasma-kinetic characteristics of purified and isolated green tea catechin epigallocatechin gallate (EGCG) after 10 days repeated dosing in healthy volunteers.

  2004cited by this paper
• Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals.

  2003influential reference
• Epigallocatechin-3-gallate is absorbed but extensively glucuronidated following oral administration to mice.

  2003cited by this paper
• Combined Lamivudine and Hepatitis B Immunoglobulin for the Prevention of Hepatitis B Recurrence after Liver Transplantation: Long‐Term Results

  2003cited by this paper
• Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines.

  2003cited by this paper
• Identification and characterization of methylated and ring-fission metabolites of tea catechins formed in humans, mice, and rats.

  2002cited by this paper
• Hepatitis C virus replication in mice with chimeric human livers

  2001cited by this paper
• Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

  1998cited by this paper
• Identification and Characterization of Broadly Neutralizing Human Monoclonal Antibodies Directed against the E2 Envelope Glycoprotein of Hepatitis C Virus (cid:1)

  year unknowncited by this paper

• Characteristics of an antibody profile associated with protection against hepatitis C virus reinfection in a high-risk cohort

  2025cites this paper
• The Role of Epigallocatechin Gallate (EGCG) in the Combating and Treat-ment of Sexually Transmitted Viral Infections.

  2024cites this paper
• Specialized metabolites from plants as a source of new multi-target antiviral drugs: a systematic review

  2023cites this paper
• Structure of the hepatitis C virus E1E2 glycoprotein complex

  2021cites this paper
• Antiviral Effects of Polyphenols from Marine Algae

  2021cites this paper
• Hepatitis C Virus Glycan-Dependent Interactions and the Potential for Novel Preventative Strategies

  2021influential citation
• In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection.

  2019cites this paper
• Emerging Frontiers of Deep Eutectic Solvents in Drug Discovery and Drug Delivery Systems.

  2019cites this paper
• Inhibitory effect of the green tea molecule EGCG against dengue virus infection

  2018cites this paper
• Hepatitis C Virus–Escape Studies for Human Monoclonal Antibody AR4A Reveal Isolate-Specific Resistance and a High Barrier to Resistance

  2018cites this paper
• Antibody Repertoire Analysis of Hepatitis C Virus Infections Identifies Immune Signatures Associated With Spontaneous Clearance

  2018cites this paper
• A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo

  2017cites this paper
• Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry

  2017cites this paper
• Promising Anti-Hepatitis C Virus Compounds from Natural Resources

  2016cites this paper
• New perspectives for preventing hepatitis C virus liver graft infection

  2016cites this paper